Unleashing the Power of Targeted Immunotherapies
for Cancer

About us

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Latest news

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting